NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Receives Average Recommendation of “Hold” from Brokerages

Posted by Brian Himes on Jul 5th, 2026

Shares of NeuroOne Medical Technologies Corporation (NASDAQ:NMTC – Get Free Report) have been given an average recommendation of “Hold” by the five research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $11.6667.

Several research firms have recently weighed in on NMTC. LADENBURG THALM/SH SH upped their price target on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Weiss Ratings lowered NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. Finally, Zacks Research cut NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 13th.

Read Our Latest Report on NMTC

Insider Activity

In other news, Director Mark Christianson sold 10,000 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $3.18, for a total transaction of $31,800.00. Following the completion of the transaction, the director owned 20,692 shares of the company’s stock, valued at approximately $65,800.56. The trade was a 32.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 11.80% of the company’s stock.

Institutional Investors Weigh In On NeuroOne Medical Technologies

Several hedge funds have recently bought and sold shares of NMTC. Legato Capital Management LLC bought a new position in shares of NeuroOne Medical Technologies in the 4th quarter worth $34,000. Squarepoint Ops LLC bought a new stake in shares of NeuroOne Medical Technologies during the 4th quarter worth $36,000. Susquehanna International Group LLP purchased a new position in NeuroOne Medical Technologies in the third quarter worth $47,000. XTX Topco Ltd purchased a new position in NeuroOne Medical Technologies in the second quarter worth $51,000. Finally, Goldman Sachs Group Inc. bought a new position in NeuroOne Medical Technologies in the first quarter valued at $84,000. 16.07% of the stock is currently owned by institutional investors.

NeuroOne Medical Technologies Stock Performance

Shares of NASDAQ:NMTC opened at $3.00 on Friday. The company has a 50 day moving average of $3.80 and a 200 day moving average of $4.38. The stock has a market cap of $26.10 million, a P/E ratio of -3.53 and a beta of 0.54. NeuroOne Medical Technologies has a 12 month low of $2.89 and a 12 month high of $6.96.

NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). NeuroOne Medical Technologies had a negative return on equity of 99.43% and a negative net margin of 68.35%.The firm had revenue of $1.86 million for the quarter, compared to the consensus estimate of $2.58 million. On average, equities analysts forecast that NeuroOne Medical Technologies will post -0.36 earnings per share for the current fiscal year.

NeuroOne Medical Technologies Company Profile

(Get Free Report)

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.